Why Is HCAT Stock Dropping Today? Health Catalyst Falls After Lowering Guidance

Health Catalyst (HCAT) shares fell 25. 43% in pre-market trading after the company cut its full-year 2026 guidance following second-quarter earnings. The lowered outlook reflects the divestiture of Vitalware and a 28.1% drop in billings.

What Happened?

Health Catalyst reported second-quarter results on August 6 and simultaneously lowered its full-year 2026 guidance. The company now expects revenue at a midpoint of $247.5 million and adjusted EBITDA at a midpoint of $18.25 million, both below prior expectations.

The revision was driven by two factors. First, the company completed the divestiture of its Vitalware business, which removes a revenue stream from the consolidated results. Second, the company disclosed a 28.1% decline in billings, pointing to operational headwinds beyond the divestiture impact.

The premarket decline on August 7 is a continuation of the sharp sell-off that began in after-hours trading on August 6, immediately following the earnings release.

Why Did Investors React?

The guidance cut signals more than a one-time adjustment for the Vitalware divestiture. The 28.1% drop in billings suggests that underlying demand may be softening, with implications for the company's growth trajectory beyond the current fiscal year.

For a healthcare data analytics company like Health Catalyst, billings are a leading indicator of future revenue. A decline of that magnitude raises questions about customer retention, new contract velocity, and the broader demand environment. The size of the revision, combined with the billings decline, caught investors off guard, and the reaction suggests the market is reassessing the company's near-term earnings power.

Market Reaction

The 25.43% premarket decline follows a sharp after-hours drop on August 6. Pre-market trading volumes are typically thinner than during the regular session, which can amplify price moves.

The regular trading session will provide a fuller picture of institutional investor reaction and whether the premarket price level holds.

Risks

The 28.1% billings decline is a significant metric that may take multiple quarters to reverse. The Vitalware divestiture creates uncertainty around the company's post-divestiture growth profile, and short-term volatility may remain elevated as the market digests the revised outlook.

What Should Investors Watch Next?

The regular trading session on August 7 will show whether institutional investors validate or fade the premarket move. Beyond the immediate price action, investors will look for additional detail on the post-divestiture business trajectory in the company's upcoming filings and any management commentary on the billings trend. Whether billings stabilize in the coming quarters will be a key factor in determining if the guidance cut is a one-time reset or the start of a longer adjustment period.